f00
[DOCID: f:h2863ih.txt]
107th CONGRESS
1st Session
H. R. 2863
To direct the Secretary of Health and Human Services to establish and
maintain a panel to provide expert scientific recommendations in the
field of cell development.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 6, 2001
Mr. McDermott (for himself and Mr. Evans) introduced the following
bill; which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To direct the Secretary of Health and Human Services to establish and
maintain a panel to provide expert scientific recommendations in the
field of cell development.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Cell Development Research Act of
2001''.
SEC. 2. FINDINGS.
The Congress finds the following:
(1) Embryonic stem cell research and therapeutic cloning
offer tremendous promise for developing cures for some of
life's most devastating diseases and disabilities, including
Parkinson's disease, Lou Gehrig's disease, Huntington's chorea,
paralysis, blindness, diabetes, and spinal cord injury.
(2) Studying the first days and the first cell divisions of
a human embryo would lead to a greater understanding of normal
and abnormal human development and of the potential for
developing therapies for congenital abnormalities.
(3) Techniques such as preimplantation genetic diagnosis
can identify embryos that are destined to develop devastating
recessive diseases, such as Fanconi's anemia and Tay-Sachs
disease.
(4) The Food and Drug Administration has jurisdiction over
certain human tissue transplantation and cloning.
SEC. 3. ESTABLISHMENT OF CELL DEVELOPMENT ADVISORY PANEL.
Subsection (n) of section 505 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(n)) is amended by adding at the end the
following:
``(9) Cell development advisory panel.--
``(A) Establishment.--The Secretary shall establish
and maintain under this subsection a single panel in
the Food and Drug Administration to provide expert
scientific advice and recommendations to the Secretary
in the field of cell development, including advice and
recommendations regarding any clinical investigation of
a drug developed as a result of research in the field
of embryology and any approval for marketing of such a
drug under this section or section 351 of the Public
Health Service Act.
``(B) Promotion of research.--Such panel shall make
policy recommendations with the goal of promoting
research in the field of cell development.
``(C) Prohibition.--Such panel shall not make any
recommendation regarding the practice of fertility
medicine.
``(D) Field of cell development.--For purposes of
this paragraph, the term `field of cell development'
includes embryonic stem cell research, therapeutic
cloning, preimplantation genetic diagnosis, and early
developmental biology.''.
<all>
0